FIELD: chemistry.
SUBSTANCE: invention relates to antibody-drug conjugates containing a cyclic dinucleotide of formula IIk, which is a STING agonist, conjugated with an antibody, methods for preparing them and using them.
EFFECT: antibody-sting agonist conjugates and their use in immunotherapy are disclosed.
39 cl, 5 dwg, 4 tbl, 7 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMPOSITIONS AND METHODS OF GENE EDITING | 2019 |
|
RU2804665C2 |
| HYBRID PROTEINS OF sPD-1-Fc VARIANT | 2019 |
|
RU2785993C2 |
| AIMED AT UPARAP ANTIBODY-DRUG CONJUGATES | 2017 |
|
RU2740311C2 |
| ERIBULIN DERIVATIVE DRUG CONJUGATE, METHOD FOR PREPARATION THEREOF AND USE THEREOF IN MEDICINE | 2021 |
|
RU2830242C1 |
| ANTIBODY-DRUG CONJUGATES CONTAINING HERBOXYDIENE-BASED SPLICING MODULATOR, AND METHODS OF USE THEREOF | 2019 |
|
RU2820607C2 |
| AMATOXIN ANTIBODY-DRUG CONJUGATES AND USE THEREOF | 2020 |
|
RU2826004C2 |
| SITE-SPECIFIC ANTIBODY-DRUG CONJUGATION BY GLYCOENGINEERING | 2014 |
|
RU2831409C2 |
| ANTIBODY-DRUG CONJUGATES INCLUDING ANTIBODY AGAINST HUMAN DLK1 AND THEIR USE | 2020 |
|
RU2801630C2 |
| DNA ANTIBODY CONSTRUCTIONS FOR USE AGAINST LYME DISEASE | 2017 |
|
RU2813829C2 |
| CONJUGATE OF ANTI-CLAUDIN ANTIBODY AND MEDICINAL AGENT AND PHARMACEUTICAL USE THEREOF | 2020 |
|
RU2826119C1 |
